

A leading global provider of products and services in apheresis collections, therapeutic apheresis and cell therapy systems, whole blood processes and pathogen reduction technologies, the company serves blood centers, hospitals and researchers in more than 90 countries with its vision, **For Better Blood and Better Lives**. Improving lives through innovation, quality and services delivered by the company's people, products and processes, CaridianBCT touches a patient's life every six seconds.

CaridianBCT leverages its technical and scientific expertise in five distinct market segments:

Apheresis Collections:

- Allowing customers to safely collect more of the specific components patients require, ensuring our customers have the right product, at the right time and in the right place.
- The Trima Accel® Automated Blood Collection System and the Vista® Information System combine to optimize donations and automate donor eligibility with versatility and real-time insight into daily collections.

Therapeutic Apheresis:

- Providing innovative technologies that separate blood components to remove disease mediators for a wide range of patient conditions.
- The Spectra Optia® Apheresis System is the next-generation therapeutic apheresis system offering gold standard COBE® Spectra Apheresis System confidence for operator control, dependability and a focus on patient care.

Cell Therapies:

- Enabling cell therapy applications around the world by providing proven tools that collect, separate, expand, wash and concentrate human cells.
- The COBE Spectra system and the Spectra Optia system's mononuclear cell collection programs* and high-yield cell therapy applications match specific patient needs with customized procedures.
- The Elutra® Cell Separation System standardizes cell enrichment, depletion and washing all in a functionally closed system, a device that complements the COBE® 2991 Cell Processor, which permits controlled, high-quality cell processing for reproducible and reliable results.
- The Quantum Cell Expansion System is a novel, flexible and automated system for growing adherent and suspension cells in a closed environment.

Whole Blood Processing:

- Bringing automation to blood component manufacturing with systems that streamline the steps involved in whole blood and Buffy Coat processing—while maximizing product quality.
- With the push of a button, the Atrius® Whole Blood Processing System produces a unit of red blood cells, plasma and platelets from a single whole blood unit.** Improving operations, the OrbiSac System* maximizes platelet product quality by streamlining Buffy Coat processing.

Pathogen Reduction Technologies:

- Delivering groundbreaking technology that proactively addresses blood safety challenges through effective pathogen reduction and white blood cell inactivation.
- The Mirasol® Pathogen Reduction Technology (PRT) System* reduces the ability of disease-causing agents to replicate in blood components intended for transfusion, enabling blood centers to confidently release high-quality blood products for timely patient care.

To learn more about how CaridianBCT aims to improve lives through better blood, visit www.caridianbct.com.